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A transplanted stem cell’s engagement with a pathologic niche is
the first step in its restoring homeostasis to that site. Inflammatory
chemokines are constitutively produced in such a niche; their bind-
ing to receptors on the stem cell helps direct that cell’s “pathotrop-
ism.” Neural stem cells (NSCs), which express CXCR4, migrate to
sites of CNS injury or degeneration in part because astrocytes and
vasculature produce the inflammatory chemokine CXCL12. Binding
of CXCL12 to CXCR4 (a G protein-coupled receptor, GPCR) triggers
repair processes within the NSC. Although a tool directing NSCs to
where needed has been long-sought, one would not inject this
chemokine in vivo because undesirable inflammation also follows
CXCL12–CXCR4 coupling. Alternatively, we chemically “mutated”
CXCL12, creating a CXCR4 agonist that contained a strong pure
binding motif linked to a signaling motif devoid of sequences re-
sponsible for synthetic functions. This synthetic dual-moity CXCR4
agonist not only elicited more extensive and persistent human
NSC migration and distribution than did native CXCL 12, but in-
duced no host inflammation (or other adverse effects); rather,
there was predominantly reparative gene expression. When co-
administered with transplanted human induced pluripotent stem
cell-derived hNSCs in a mouse model of a prototypical neurode-
generative disease, the agonist enhanced migration, dissemina-
tion, and integration of donor-derived cells into the diseased
cerebral cortex (including as electrophysiologically-active cortical
neurons) where their secreted cross-corrective enzyme mediated a
therapeutic impact unachieved by cells alone. Such a “designer”
cytokine receptor-agonist peptide illustrates that treatments can
be controlled and optimized by exploiting fundamental stem cell
properties (e.g., “inflammo-attraction”).
human induced pluripotent stem cells | neural stem cells | CXCR4 |
neurodegeneration | homing
Atransplanted stem cell’s engagement with a pathologic nicheis the first step in cell-mediated restoration of homeostasis
to that region, whether by cell replacement, protection, gene
delivery, milieu alteration, toxin neutralization, or remodeling
(1–4). Not surprisingly, the more host terrain covered by the stem
cells, the greater their impact. We and others found that a pro-
pensity for neural stem cells (NSCs) to home in vivo to acutely
injured or actively degenerating central nervous system (CNS)
regions—a property called “pathotropism” (1–12), now viewed as
central to stem cell biology—is undergirded, at least in part, by the
presence of chemokine receptors on the NSC surface, enabling
them to follow concentration gradients of inflammatory cytokines
constitutively elaborated by pathogenic processes and expressed
by reactive astrocytes and injured vascular endothelium within the
pathologic niche (5–9). This engagement of NSC receptors was
first described for the prototypical chemokine receptor CXCR4
(C-X-C chemokine receptor type 4; also known as fusin or cluster
of differentiation-184 [CD184]) and its unique natural cognate
agonist ligand, the inflammatory chemokine CXCL12 (C-X-C
motif chemokine ligand-12; also known as stromal cell-derived
factor 1α [SDF-1α]) (5), but has since been described for many
chemokine receptor-agonist pairings (6–9). Chemokine receptors
belong to a superfamily that is characterized by seven trans-
membrane GDP-binding protein-coupled receptors (GPCRs)
(13–21). In addition to their role in mediating inflammatory re-
actions and immune responses (22, 23), these receptors and their
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cells, one would certainly not want to further “inflame” a dis-
eased brain by instilling such molecules. Exploiting the fact that
receptors for such cytokines (G protein-coupled receptors
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agonists are components of the regulatory axes for hematopoiesis
and organogenesis in other systems (21, 24). Therefore, it is not
surprising that binding of CXCL12 to CXCR4 mediates not only
an inflammatory response, but also triggers within the NSC a se-
ries of intracellular processes associated with migration (as well as
proliferation, differentiation, survival, and, during early brain de-
velopment, proper neuronal lamination) (10).
A tool directing therapeutic NSCs to where they are needed
has long been sought in regenerative medicine (11, 12). While it
was appealing to contemplate electively directing reparative
NSCs to any desired area by emulating this chemoattractive
property through the targeted injection of exogenous recombi-
nant inflammatory cytokines, it ultimately seemed inadvisable to
risk increasing toxicity in brains already characterized by exces-
sive and usually inimical inflammation from neurotraumatic or
neurodegenerative processes. However, the notion of engaging
the homing function of these NSC-borne receptors without
triggering that receptor’s undesirable downstream inflammatory
signaling [particularly given that the NSCs themselves can exert a
therapeutic antiinflammatory action in the diseased region (1,
2)] seemed a promising heretofore unexplored “workaround.”
There had already been an impetus to examine the structure–
function relationships of CXCR4, known to be the entry route into
cells for HIV-1, in order to create CXCR4 antagonists that block
viral infection (25–30). Antagonists of CXCR4 were also devised
to forestall hematopoietic stem cells from homing to the bone
marrow, hence prolonging their presence in the peripheral blood
(31) to treat blood dyscrasias. An agonist, however, particularly
one with discrete and selective actions, had not been contem-
plated. In other words, if CXCL12 could be stripped of its un-
desirable actions while preserving its tropic activity, an ideal
chemoattractant would be derived.
Based on the concept that CXCR4’s functions are conveyed by
two distinct molecular “pockets”—one mediating binding (i.e.,
allowing a ligand to engage CXCR4) and the other mediating
signaling (i.e., enabling a ligand, after binding, to trigger
CXCR4-mediated intracellular cascades that promote not only
inflammation but also migration) (13–18)—we performed chem-
ical mutagenesis that should optimize binding while narrowing the
spectrum of signaling. We created a simplified de novo peptide
agonist of CXCR4 that contained a strong pure binding motif
derived from CXCR4’s strongest ligand, viral macrophage in-
flammatory protein-II (vMIP-II) and linked it to a truncated
signaling motif (only 8 amino acid residues) derived from the N
terminus of native CXCL12 (19, 20). This synthetic dual-moiety
CXCR4 agonist, which is devoid of a large portion of CXCL12’s
native sequence (presumably responsible for undesired functions
such as inflammation) not only elicited (with great specificity)
more extensive and long-lasting human NSC (hNSC) migration
and distribution than native CXCL12 (overcoming migratory
barriers), but induced no host inflammation (or other adverse
effects). Furthermore, because all of the amino acids in the
binding motif were in a D-chirality, rendering the peptide re-
sistant to enzymatic degradation, persistence of this benign
synthetic agonist in vivo was prolonged. The hNSC’s gene on-
tology expression profile was predominantly reparative in con-
trast to inflammatory as promoted by native CXCL12. When
coadministered with transplanted human induced pluripotent
stem cell (hiPSC)-derived hNSCs (hiPSC derivatives are now
known to have muted migration) in a mouse model of a proto-
typical neurodegenerative disease [the lethal neuropathic lyso-
somal storage disorder (LSD) Sandhoff disease (29), where
hiPSC-hNSC migration is particularly limited], the synthetic ag-
onist enhanced migration, dissemination, and integration of
donor-derived cells into the diseased cortex (including as elec-
trophysiologically active cortical neurons), where their secreted
cross-corrective enzyme could mediate a histological and functional
therapeutic impact in a manner unachieved by transplanting hiPSC-
derived cells alone.
In introducing such a “designer” cytokine receptor agonist, we
hope to offer proof-of-concept that stem cell-mediated treat-
ments can be controlled and optimized by exploiting funda-
mental stem cell properties (e.g., “inflammo-attraction”) to alter
a niche and augment specific actions. Additionally, when ago-
nists are strategically designed, the various functions of chemo-
kine receptors (and likely other GCPRs) may be divorced. We
demonstrate that such a strategy might be used safely and ef-
fectively to direct cells to needed regions and broaden their
chimerism. We discuss the future implications and uses within
the life sciences of such a chemical engineering approach.
Results
Designing a Synthetic “Purely” Chemoattractant CXCR4 Agonist.
CXCL12 is comprised of an N-loop, a 30’s loop, and an anti-
parallel β-sheet with three β-strands adjacent to a C-terminal
α-helix. It is thought that the N terminus of CXCL12’s globu-
lar core structure engages CXCR4 and is mainly responsible for
both binding to CXCR4 and triggering its signaling (13–16)
(Fig. 1). Studies by many groups, including our own, have sug-
gested that CXCR4 possesses two different “pockets” within its
seven-transmembrane helices with which CXCL12 interacts: One
mediating binding, the other signaling (13–19, 25–27). In a
complimentary manner, two different regions of CXCL12’s N
terminus, respectively, engage each CXCR4 pocket indepen-
dently, first binding and then signaling (19–21, 24–27). Based on
this model, we designed (as detailed below and schematized in
Fig. 1B) CXCL12 “mimics” that might be solely “promigratory”
by inserting CXCR4’s strongest binding motifs but retaining only
the most minimal and selective of signaling sequences (Figs. 1B
and 2 A and B).
We began by choosing a high-affinity binding motif. Recogniz-
ing that the strongest “binder” to CXCR4 is actually its antagonist,
the viral chemokine vMIP-II that stimulates no signaling activity
(28) (Fig. 2B), we substituted vMIP-II’s receptor binding sequence
(located at its N terminus) for CXCL12’s corresponding natural
binding motif (Fig. 1B). To determine the proper vMIP-II resi-
dues, we performed a series of CXCR4 in silico molecular docking
studies analyzing the interaction between CXCR4 and different
small 21-mer all–D-chirality amino acid peptide derivatives of the
N-terminal residue of vMIP-II, creating a family of synthetic li-
gands (collectively called “DV”), each with a different D-(1∼21)-
vMIP-II binding moiety (Fig. 2A). The various peptides were
modeled making contact with the binding and signaling pockets of
CXCR4 using computational methods (32–35) to determine which
made maximal contact with the former without binding the latter.
One DV family member was selected, DV1, based on its energy-
favorable initial-stage docking profile. Over a 5-ns molecular dy-
namics (MD) simulation, backbone atoms of both the ligand and
the receptor showed consistently lower RMSD (i.e., small RMS
fluctuations) (Fig. 2 A, a), denser hydrogen bond formation
(Fig. 2 A, b and d), and stronger electrostatic and van der Waals
interactions at the binding pocket compared to the signaling
pocket (Fig. 2 A, c). Specifically, at the binding pocket, Leu1 of
DV1 formed hydrogen bonds with Tyr256 and Glu288 of CXCR4;
Gly2, Ala3, and Ser4 of DV1 formed many hydrogen bonds with
Glu288 of CXCR4; Ala3 also formed a hydrogen bond with
Gln272. Arg7 of DV1 formed three hydrogen bonds with Ala98
and Trp102 of CXCR4 (Fig. 2 A, d, Left). There were also many
hydrophobic interactions between DV1 and CXCR4; for example,
Leu1 of DV1 with Tyr116 and Tyr256 of CXCR4, Ala3 of DV1
with Ser285 of CXCR4, and Trp5 of DV1 with Tyr103, Phe104,
Tyr184, Phe189 of CXCR4; Pro8 of DV1 with Cys28 of CXCR4
(Fig. 2 A, d, Left). These findings indicated a more favorable and
selective interaction between DV1 and CXCR4’s binding pocket
31178 | www.pnas.org/cgi/doi/10.1073/pnas.1911444117 Lee et al.
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than with its signaling pocket, an encouraging basis for the
dual-moiety agonist we were attempting to design.
Because the N terminus of DV1 would now form fewer polar
interactions with CXCR4’s signaling pocket than does native
CXCL12 (Fig. 2 A, d, Right), that pocket could now become
available, after DV1 binding, for interactions with a separate
signaling motif from the environment, and hence potentially
activate unintended and undesirable full signaling. Accordingly,
the next step in our design was to occupy that signaling pocket
but do so by using the signaling portion of the N terminus of
native CXCL12 truncated from a 68-mer to merely an 8-mer
peptide [that nevertheless retained the first 2 amino acid resi-
dues, which are essential for signaling (13, 14)]. Therefore, this
shortened peptide, which we called S1, could occupy CXCR4’s
signaling pocket but narrow the spectrum of CXCR4 signaling.
Because DV1 was positioned and synthetically coupled to
the C-terminal end of S1, this new hybrid peptide was called
SDV1.
To ensure an appropriate spatial arrangement of the two linked
peptide moieties for optimally performing their respective binding
and signaling functions, different spacer sequences were inserted
between them, yielding three candidates—designated SDV1a,
SDV1b, and SDV1c—which might serve as our new bifunctional
agonist (see SI Appendix, Table S1 for sequences). These candi-
dates were synthesized, their purity confirmed with high-
performance liquid chromatography, and their molecular weights
validated by matrix-assisted laser desorption/ionization-time of
flight mass spectrometry (SI Appendix, Fig. S1).
Chemical and Molecular Characterization of the Synthetic CXCR4
Agonists. We next determined the CXCR4-selective binding ef-
ficiency of these candidates by comparing their ability to outcom-
pete the binding of a fluorophore-conjugated anti-CXCR4–specific
monoclonal antibody (Clone 12G5) to cells that highly express
CXCR4 and are the literature’s standard for CXCR4-expressing
cells (the Sup-T1 human lymphoma T-cell line) (28). All three
peptides exhibited high CXCR4-binding potency in this 12G5-
based competitive receptor binding assay (SI Appendix, Fig. S2A)
with an IC50 ranging from lower micromolar to submicromolar
concentrations (SI Appendix, Fig. S2B), a bit less than the an-
tagonist DV1 alone but greater than the S1 truncated signaling
portion alone.
Next, we evaluated the candidates’ relative signaling capac-
ities. As with other GPCRs, binding of an agonist to CXCR4
causes a catalytic exchange of GDP for GTP by dissociation of
the G protein’s linked trisubunits; the G α-subunit regulates cell
surface receptor dynamics, while the G β- and γ-subunits regu-
late MAPK signaling via the gating of intracellular calcium
(Ca2+i) (7) [which, in turn, controls other intracellular second
messengers, e.g., IP3 and cAMP (21)]. We, therefore, measured
the dose-dependent Ca2+ efflux kinetics of Sup-T1 cells treated
with these synthetic “dual-moiety” CXCR4-binding peptides.
Signaling amplitude was probed with a dual-wavelength Ca2+
indicator Fura-2/AM using ratiometric conversions of Ca2+
concentrations inside the cytosolic environment (Fig. 2B and SI
Appendix, Fig. S2C). Measurements were made using a fluores-
cence plate-reader facilitated by an automated liquid handling
system. Both SDV1a and SDV1c (but not SDV1b) elevated Ca2+
efflux with increasing concentrations (SI Appendix, Fig. S2 C, ii),
implying activation of MAPK signaling, which leads to a cascade
of multiple downstream intracellular events, including but not
limited to cell motility (36, 37). The amount of Ca2+ efflux
(i.e., signaling), however, was dramatically less than the signaling
induced by natural CXCL12, one of our goals (SI Appendix, Fig.
S2 C, i). In contrast, SDV1a’s truncated “signaling moiety” (S1)
alone required a 100-fold greater concentration than natural
CXCL12 and a 10-fold greater concentration than SDV1a to
elicit comparable Ca2+ release (SI Appendix, Fig. S2 C, iii). The
“binding moiety” alone from antagonist vMIP-II (DV1), as
expected, evoked no signaling, even at concentrations as high as
40 μM (SI Appendix, Fig. S2 C, iii).
Impact on Cells of Candidate Synthetic CXCR4 Agonists. Finally, we
assessed the candidates’ relative capacities to promote cellular
migration using a Boyden chamber chemotaxis assay. With a
porous (8 μm) membrane separating the upper from the lower
chamber, Sup-T1 cells were placed in the former and the can-
didate peptides (at titrated concentrations) placed in the latter
(SI Appendix, Fig. S2D, schematic). (Note: hNSCs replaced Sup-
T1 cells in subsequent experiments once a candidate was selected).
Dose-dependent cell migration from the upper to the lower
chamber was elicited by all three bifunctional peptide candidates
(SI Appendix, Fig. S2D) (S1 and DV1, as expected, elicited no
chemotaxis). Preincubation of the cells with the CXCR4-specific
blocking antibody 12G5 suppressed migration, suggesting that
CXCR4 was mediating this response. As an additional control, in
Synthetic “pure” chemoattractant CXCR4 agonist peptide
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Fig. 1. Design of a synthetic purely chemoattractant CXCR4 agonist. (A)
Normally, the intact chemokine agonist CXCL12 (also known as SDF1α) binds
to its receptor, CXCR4, in two steps to two different pockets, respectively.
After initial binding of the proximal N terminus of CXCL12’s globular core
structure to the binding pocket in CXCR4’s extracellular transmembrane
regions, CXCL12’s distal N terminus reaches CXCR4’s transmembrane sig-
naling pocket and leads to allosteric modulation of CXCR4’s conformation
which, in turn, enables canonical receptor functions, including activating
multiple downstream G protein-mediated signaling pathways (adapted with
permission from ref. 13). (B) Strategy for synthesizing SDV1a, a dual-moiety
bifunctional hNSC chemoattractant with maximal binding and negligible
inflammatory, yet preserved reparative stem cell-related signaling. The first
21 amino acids (all in a D-chirality) from the N terminal of the CXCR4 an-
tagonist vMIP-II, were inserted in place of CXCL12’s proximal N terminus in
order to provide a ligand with the highest possible affinity for the binding
pocket (green circle); it promotes no signaling (Fig. 2D). It was called DV1.
The distal N-terminal signaling motif of CXCL12, which engages the signal-
ing pocket (red circle), was truncated to the first 8 amino acids (including the
first 2 amino acids required for signaling) in order to narrow the spectrum of
G protein-mediated pathways activated to those supportive of cell prolif-
eration, migration, and survival (e.g., MAPK) while excluding (or minimizing)
those involved in inflammatory cascades (SI Appendix, Figs. S4, S6, and S7).
This truncated signaling motif was called S1. Therefore, the designer peptide
was designated L-(1∼8)-SDF1α-GG-D-(1∼21)-vMIP-II, or SDV1a for short.
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some conditions a test candidate was added to the upper chamber
or to both chambers; the greatest migration was observed when
the peptide was present only in the lower chamber, suggesting
chemotaxis (rather than spontaneous random cell motility) as the
predominant mechanism for transmigration of the cells (SI Ap-
pendix, Fig. S2 D, Right Inset). Based on efficiency of binding,
potency in eliciting cell migration yet modulated degree of MAPK
signaling, we chose SDV1a as the bifunctional dual moiety syn-
thetic peptide agonist for use in all subsequent in vitro and in vivo
experiments involving hNSCs with an eye toward translational
applications.
Impact on hNSCs of the Synthetic CXCR4 Agonist Peptide SDV1a.
Although previously documented (8), we reconfirmed abun-
dant expression of CXCR4 on primary fetal brain-derived hNSCs
(1–3, 5, 38, 39) (SI Appendix, Fig. S3). We next determined
whether SDV1a’s actions on hNSCs were comparable to those of
CXCL12 (5). First, we investigated whether SDV1a triggered the
same intracellular CXCR4-mediated downstream signaling cas-
cades as CXCL12 (5). Western blot analysis was performed on
lysates from hNSCs prestimulated with either SDV1a or
CXCL12 to assess changes in the phospho-kinetics of several
cardinal proteins downstream of CXCR4 (SI Appendix, Fig. S4).
As with CXCL12, we observed rapid (within 2 to 5 min) phos-
phorylation (at Tyr202 and Tyr204) of the extracellular signal-
regulated kinases 1/2 (ERK1/2) by SDV1a, suggesting that, in
subsequent experiments, we should expect to see—as we did with
CXCL12 (5)—induction of such relevant ERK1/2-downstream
activities as cell motility (5, 36, 40) (SI Appendix, Fig. S4 A and
B). Also phosphorylated were p38-MAPK (at Thr180/Tyr182)
and IκBα (inhibitor of NF-κB α) (at Ser-32/36) (SI Appendix, Fig.
S4C), as we previously reported for CXCL12’s action on the very
same hNSC clones (5). It is telling that these “reparative” cas-
cades within hNSCs could be triggered despite the fact that
signaling following SDV1a exposure, as assayed by Ca2+ efflux,
was an order-of-magnitude less than following recombinant
CXCL12 exposure (Fig. 2B and SI Appendix, Fig. S5). SDV1a’s
action (which is dose-dependent) (Fig. 2C) was blocked by pre-
treatment of the hNSCs with AMD3100, a small-molecule
CXCR4-specific inhibitor (which desensitizes CXCR4 to ago-
nist activation) (31), confirming a CXCR4-specific mechanism of
action (Fig. 2D and SI Appendix, Fig. S5).
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Fig. 2. Chemical and molecular characteristics of the synthetic CXCR4 ag-
onist peptide SDV1a. (A) MD simulation in silico of interactions between the
synthetic binding peptide DV1 and CXCR4. Briefly, a CXCR4 homology model
was constructed and docking simulations were performed among 60 po-
tential peptides derived from vMIP-II. The most energy-favorable candidates
were chosen, as illustrated here for DV1 (the one ultimately selected). MD
simulations (5 ns) of this complex with CXCR4 were then performed. (a)
RMSD analysis of backbone atoms of CXCR4 and DV1 showing their fluctu-
ations over time. It is greater at the binding site. (b) Number of hydrogen
(H-) bonds formed between DV1 and CXCR4 over time. More are formed at
the binding site. (c) Electrostatic (Coul-SR) and van derWaals (LJ-SR) interaction
energies between DV1 and CXCR4. These are stronger at the binding site. (d)
Two-dimensional Ligplot results showing that the N-terminal residues of DV1
form more polar interactions with CXCR4 at the binding pocket (Left) than at
the signaling pocket (Right) by the end of the simulation. (B) SDV1a induces
modulated signaling. Because activation of Ca2+ efflux is downstream of GPCR
activation of Ca2+ channels, Ca2+ mobilization assays can serve as surrogates
for signaling. Shown is ratiometric [Ca2+]i release from the literature’s standard
CXCR4-expressing cell line, Sup-T1, as measured by Fura-2/AM fluorescence
intensity following treatment with: 1) Full-length CXCL12/SDF1α (red circle), 2)
SDV1a (green triangle), or 3) the components of SDV1a in isolation, its binding
motif (derived from the antagonist vMIP-II [DV1]) (purple square) and its
truncated signaling motif (S1) (blue triangle). As expected, the natural agonist
CXCL12/SDF1α produced the most intense signaling, while the antagonist
produced none. When S1 was combined with DV1, however, to create SDV1a,
ideally modulated signaling was obtained (an order-of-magnitude less than
CXCL12/SDF1α), yielding an optimal signaling profile. (See SI Appendix, Fig.
S2C for an expanded presentation of these data, and SI Appendix, Figs. S4
and S6 for the molecular consequences of this signaling.) These findings, taken
together with SDV1a’s also having the strongest affinity for CXCR4 among the
candidates (SI Appendix, Fig. S2B), led to SDV1a’s use in all subsequent exper-
iments, particularly those performed in vivo. Shown are the mean values of
three technical replicates from one of at least three independent biological
replicates. Error bars represent ± SEM. (C) Effect of different SDV1a doses on
CXCR4-mediated Ca2+ mobilization (efflux). SDV1a triggered a typical Ca2+
spike in CXCR4-expressing cells in a dose-dependent manner. The EC50 of
calcium efflux was between 2 and 5 μM, consistent with its binding IC50 (as
per SI Appendix, Fig. S2B). (D) Blocking CXCR4 inhibits activation of Ca2+
signaling by SDV1a. See SI Appendix, Fig. S5 for experimental details and
an expanded presentation of these data, including from other control con-
ditions. Briefly, single hNSCs, loaded with Fura-2/AM, were measured for a
340/380 ratio of free [Ca2+]i. Calculated changes in [Ca
2+]i were expressed in
arbitrary units. A peak was defined as a fluorescence ratio increase at least
three times greater than the noise level for the same cell. SDV1a (10 μM)
increased [Ca2+]i (Left), whereas AMD3100 (100 μM), a CXCR4-specific
blocker, reduced the [Ca2+]i if added just prior to SDV1a exposure (Right),
even at SDV1a’s highest dose (as determined in C). Each panel shows the
result of a single cell’s transient [Ca2+]i release but represents the results of
at least 11 cells per condition.
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We next used flow cytometry (FACS) of live hNSCs to mon-
itor the dynamics of CXCR4 cell surface expression (i.e., the
kinetics of receptor endocytosis and reappearance) following li-
gand binding (41), comparing SDV1a with CXCL12. Under both
conditions, there was a transient elevation followed by a down-
regulation of CXCR4 surface expression; however, the kinetics
of this endocytosis/reexpression cycle differed for the two li-
gands. CXCR4 recycling was slower and surface expression more
persistent following SDV1a stimulation (Fig. 3 A, Upper) than
following CXCL12 induction (Fig. 3 A, Lower), suggesting that
hNSCs may be poised to experience a more protracted chemo-
attractive “pull” from the synthetic agonist. Furthermore, as
endocytosis of GPCRs is required for canonical G protein and
β-arrestin–mediated CXCR4 signaling, this finding of longer cell
surface expression of CXCR4 and quicker surface reexpression
may also contribute to our goal of muting certain undesirable
downstream actions of CXCR4 that occur intracellularly (e.g.,
minimizing GPCR-mediated inflammatory cascades) in favor of
reparative ones.
To explore this possibility further, differential gene-expression
analysis using gene ontology terms was performed on hNSCs
exposed to SDV1a compared to those exposed to CXCL12. As
expected, there was some overlap in regulated genes (SI Ap-
pendix, Fig. S6 A and B). Under both conditions, the most highly
ranked genes were those involved in cytoskeleton reorganization,
(e.g., regulation of cell cycle, adhesion and proliferation, keratin
filament formation, and epithelial-to-mesenchymal transition).
But, also telling were differences in the hierarchy of cellular
events promoted: Prominent in hNSCs treated with CXCL12 was
up-regulation of inflammatory and immune-related processes,
such as IFN-α/β signaling, stimulation of arachidonic acid pro-
duction, and hypoxia-related functions, which were not prom-
inent following treatment with SDV1a (SI Appendix, Fig. S6C).
Rather, SDV1a primarily induced genes associated with devel-
opmental, homeostatic, and stem cell-related functions (SI Ap-
pendix, Fig. S7). (A detailed study of the molecular regulation of
the multiple GPCR-mediated downstream pathways implicated
is beyond the scope of the present paper.)
We next determined SDV1a’s action on actual hNSC behav-
ior. We had previously reported (8) that exposure of hNSCs to
CXCL12 and the consequent induction of CXCR4-mediated
signaling triggers a series of intracellular processes associated
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Fig. 3. Impact on hNSCs of the synthetic CXCR4 agonist peptide SDV1a. (A)
Flow cytometric analysis of CXCR4 surface expression, endocytosis, and
recycling in hNSCs activated by SDV1a vs. CXCL12/SDF1α over time. As shown
in this receptor endocytosis analysis, when bound by either ligand (4 μg/mL),
there was a dynamic recycling of cell surface CXCR4. However, the kinetics of
endocytosis of CXCR4 was slower in response to SDV1a, taking 90 min to
down-regulate (Upper). In contrast, CXCL12 binding induced down-
regulation of CXCR4 expression on the hNSC surface rapidly, within the
first 10 min; cell surface CXCR4 did not start to rebound until after 45 min
(Lower). This difference meant that the surface expression of CXCR4 on
hNSCs was more prolonged following binding by SDV1a than by natural
CXCL12 (red arrows, Upper), suggesting that hNSCs may be poised to ex-
perience a more protracted chemoattractive pull from the synthetic agonist.
Furthermore, as endocytosis of GPCRs is required for canonical G protein-
and β-arrestin-mediated CXCR4 signaling, this finding of longer cell surface
expression of CXCR4 and quicker surface reexpression (i.e., a shorter time
spent intracellularly) may also contribute to muting certain undesirable
downstream actions of CXCR4 within these hNSCs (e.g., minimizing GPCR-
mediated inflammatory cascades). (B–E) In assays comparing their chemo-
attractive actions upon hNSCs, SDV1a matched the efficacy of native CXCL12
(SDF1α). (B) A Boyden chamber transmigration assay was used in which
hNSCs (1 × 105 in 100 μL medium) were placed in the upper chamber and the
agent to be tested (in 600 μL medium) was placed in the bottom chamber.
The chambers were separated by a 6.5-mm-diameter 8-μm pore-size trans-
well insert coated with fibronectin (1 μg/cm2). After 5 h of incubation, hNSCs
that had migrated from the upper to the lower chamber and attached to the
bottom of the transwell insert were fixed, stained with Crystal violet, and
counted. A migration index was calculated by comparing the number of cells
that migrated in response to a test chemoattractant peptide vs. to medium
alone. (C) The migratory index of hNSCs confronted with SDV1a was similar
to that for CXCL12/SDF1α in a Boyden chamber. Both agonists produced a
typical bell-shaped dose–response, with chemotaxis peaking at 5 nM for
SDV1a and at 0.5 nM for CXCL12, consistent with their 10-fold differences
in signaling intensity. Results shown represent the mean values at least two
independent biological replicates, each with three technical replicates per
experiment (**P < 0.05, one-tailed Student’s t test, ± SEM). (See SI Appendix,
Fig. S2D for an expanded presentation of these data with additional exper-
imental conditions.) (D) Preincubation of the hNSCs with the CXCR4-specific
blocking antibody 12G5 suppressed the promigratory actions of both
CXCL12 and SDV1a, suggesting that CXCR4 binding and activation were
mediating the chemoattractive actions for both agents. Results shown rep-
resent the mean values at least two independent biological replicates, each
with three technical replicates per experiment (*P < 0.05, one-tailed Stu-
dent’s t test, ± SEM). (E) hNSCs migrated in response to a SDV1a concentra-
tion gradient based on chemoattraction and not spontaneous random cell
motility. hNSCs seeded into the top chamber of the Boyden chamber (B)
preferentially migrate toward SDV1a added into the lower chamber (creat-
ing a concentration gradient) as opposed to its being added into the upper
chamber or into both chambers (abrogating an SDV1a concentration gradi-
ent). Results represent at least two independent biological replicates, each
with three technical replicates per experiment (±SD) (*P < 0.05). See SI Ap-
pendix, Fig. S2D for additional experimental conditions.
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with fundamental aspects of stem cell proliferation and migra-
tion. Would SDV1a do the same?
With regard to proliferation, SDV1a (10 nM), when added for
72 h to hNSCs in a CyQuant proliferation assay, increased total
DNA content by 10% compared to untreated controls, similar to
the effect of recombinant human CXCL12 protein. In the above-
described Boyden chamber assay of chemotaxis (Fig. 3B), the
promigratory actions of SDV1a were indistinguishable from
those of CXCL12, both evincing a typical bell-shaped dose-
dependence, with chemotaxis peaking at 5 nM for SDV1a and
at 0.5 nM for CXCL12 (Fig. 3C). Preincubation of the hNSCs
with the above-mentioned CXCR4-specific blocking antibody
12G5 abrogated the promigratory actions of both ligands
(Fig. 3D), suggesting that CXCR4 binding and activation were
mediating the chemoattraction for both agents. Again, as an
additional control, SDV1a was added to the upper chamber
(where the hNSCs were seeded) or to both chambers (abrogating
a concentration gradient); hNSC migration (upper to lower
chamber) was observed only when SDV1a was present in the
lower chamber, implicating chemotaxis (rather than solely
spontaneous random cell motility) as the likely mechanism for
hNSC transmigration in response to SDV1a (Fig. 3E).
Transplanted hNSCs Are Drawn to SDV1a across Large Distances in
the Adult Brain. Based on SDV1a’s actions on hNSCs in vitro
(compared to those of CXCL12), we expected that, if administered
in vivo, SDV1a would attract transplanted hNSCs as efficiently as
we reported for naturally expressed CXCL12 (5) but without pro-
voking an inflammatory reaction. [It should be noted that, although
SDV1a required a 10-fold higher dose to achieve the same degree
of chemotaxis in vitro—consistent with its 10-fold lower signaling
based on Ca2+ efflux (Figs. 2 B–D and 3C and SI Appendix, Fig.
S5)—the logistics of administering what is still a very small volume
dose (1 to 2 μL in an adult rodent), given the absence of adverse
effects (see below), was deemed trivial and minimally invasive.] To
make our observations unambiguous and minimize confounders, we
first tested SDV1a under very stringent conditions, in the uninjured,
nonpathologic adult mammalian brain, which normally does not
support extensive migration of NSCs (6, 8) (Fig. 2). We asked
whether SDV1a injected into the adult murine cortex (we treated two
separate cortical regions to avoid unwittingly choosing a favorable
location) or hippocampus would attract hNSCs transplanted at a
distance: For example, into the contralateral hippocampus, a site
of adult rodent neurogenesis that might theoretically prompt
hNSCs to resist the pull of the peptide. SDV1a did, indeed, attract
the hNSCs to all regions where it was injected (Fig. 4, Left, regions
i–iii), in contrast to injected PBS (a sham negative control for
ruling out the effect of tissue damage from needle insertion
alone), which drew no hNSCs (Fig. 4, Right, regions i–iii), and in
contrast to recombinant CXCL12, which also, surprisingly, drew
no hNSCs (for reasons explained below), yielding a picture iden-
tical to Fig. 4, Right, regions i–iii. Other comparisons with
CXCL12 were also striking, as described below.
To provide more detail, 2 wk postengraftment transplanted
hNSC-derived cells (as detected by human-specific mitochon-
drial [hMito] immunoreactivity) (1) were abundantly and widely
distributed throughout the cortical parenchyma and hippocam-
pus contralateral to their implantation site, congruent with
SDV1a’s distribution (detailed below) (Figs. 3A and 4, Left), and
persisted throughout the lifetime of the mouse, indicating that
the synthetic agonist SDV1a had successfully drawn the hNSCs
to the targeted area where it had been administered, overcoming
barriers to NSC migration. (The differentiation fate of engrafted
hNSCs is more extensively explored below and in Fig. 8 and SI
Appendix, Fig. S9). Nearly all implanted hNSCs migrated toward
the SDV1a injection site in the contralateral hemisphere, with
negligible (if any) remaining and integrating at the point of im-
plantation on the side opposite to that of the SDV1a injection.
With an engraftment efficiency of ∼50% for hNSCs in the tel-
encephalon [as previously reported (4)], the expected ∼1.0 × 105
donor-derived hMito+ cells were appreciated throughout con-
tralateral regions i to iii (Fig. 4, Left), the same regions i to iii
demarcated in Fig. 5A as SDV1a’s distribution (see below for
greater detail).
If hNSCs were pretreated prior to transplantation with either a
CXCR4 inhibitor (AMD3100) (31) or a CXCR7 inhibitor
Fig. 4. Transplanted hNSCs are drawn to SDV1a
across large distances in the adult mammalian brain.
WT intact adult (6- to 8-wk old) C57BL/6J mice were
implanted (by stereotaxic guidance to the location
indicated in the schematics) with hNSCs (2 μL from a
1 × 105cells/μL dissociated cell suspension) contem-
poraneously with injections (into the three contra-
lateral regions indicated in the schematics) of either
SDV1a (Left) or PBS (sham control) (Right). (i =
hippocampus; ii and iii = two different regions of
cortex). Coronal sections (20 μm) were analyzed
immunohistochemically from each region to detect
hNSCs that had migrated from the opposite hemi-
sphere, using the well-established hMito (red) (1) at
various time intervals posttransplant, ranging from 2
wk (shown here) to 4 mo. See Insets for magnified
images hNSC-derived hMito-immunopositive cells
(red), demonstrating their unambiguous cytoplasmic
appearance in relation to DAPI+ nuclei (blue). With
the exception of the rostral migratory stream, the
intact adult rodent brain does not usually support
long-distance migration of NSCs in the cerebrum.
However, as shown, Left, transplanted hNSCs mi-
grated to the multiple contralateral regions injected
with SDV1a. No such migration occurred when PBS
was injected into regions i to iii; no hNSCs were
evident there (Right), an appearance identical, as
well, to that following injection of recombinant CXCL12 into those regions (see section of text entitled Transplanted hNSCs Are Drawn to SDV1a across
Large Distances in the Adult Brain for explanation). (Scale bars, 25 μm.) (Data from mice who received injections of SDV1a without hNSCs are shown in SI
Appendix, Fig. S8.)
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(CCX771) (the latter representing another chemokine receptor
for CXCL12), hNSC migration to SDV1a was abrogated only
with the former (Fig. 3B), suggesting that SDV1a was acting
highly specifically through CXCR4 directly on the hNSCs and
not through other cytokine receptors or through intermediaries
(e.g., receptors on macroglia, microglia, extracellular matrix,
vascular endothelia, and so forth).
Interestingly, as noted above, injection of exogenous recombi-
nant human CXCL12 using the same procedure did not trigger
comparable hNSC migration. An explanation for this difference
may be found in the distribution and persistence of SDV1a
compared to that of recombinant CXCL12. The cortical location
of the engrafted hNSCs in response to SDV1a was, as noted
above, congruent with SDV1a’s distribution as detected by
FITC-labeled SDV1a (Fig. 5 A, Left) and biotinylated SDV1a
(Fig. 5 A, Right), which persisted for 3 wk postadministration. In
contrast, recombinant CXCL12, similarly labeled, was undetectable
by 2 d postadministration. This greater stability and persistence of
SDV1a compared to recombinant CXCL12 might be attributable to
its greater resistance to in vivo enzymatic degradation compared to
CXCL12 (18) because of its unnatural amino acid composition; all
amino acids in the DV1 binding motif are in a D-chirality. This
short half-life for natural endogenous CXCL12 is transiently com-
pensated for in vivo immediately following an injury by its being
replenished recurrently by reactive astrocytes and vascular endo-
thelium, as we previously reported (8); however, therapeutically,
one could not—nor want to—rely on this mechanism for renewal.
The pharmacokinetics of SDV1a was consistent with rapid dis-
semination (by 30 min postinjection) throughout the regions illus-
trated in Fig. 4, i–iii and 5A with a Cmax of 11.3 ± 1.3 μM/gm of
brain tissue.
SDV1a’s persistence may also be ascribed to another striking
difference between brains injected with SDV1a compared to
those that received CXCL12 (and, indeed, one of our goals): The
diminished degree of activated microgliosis engendered by the
former compared to the latter. As suggested by SDV1a’s induced
gene-expression profile with a much reduced inflammatory sig-
nature (SI Appendix, Figs. S6 and S7), SDV1a evoked little, if
any, microglial reactivity (Fig. 5 C, Left), hence triggering fewer
counteractive host responses to eliminate an “inciter.” Microglia
are early sensors of pathology and thus are the principal cellular
mediators of inflammation in the brain. Activated resident
microglial cells and recruited macrophages from the vascular
compartment generate toxic products, such as oxygen-free radi-
cals, nitric oxide, and neurotoxic cytokines (e.g., TNF-α, MIP1α,
and IL-1β). Hence, monitoring the appearance of activated
microglia is an excellent bellwether of an inflammatory milieu.
The brains of mice receiving CXCL12 were characterized by a
vast reactive M1 microgliosis [as determined not only by their
immunostaining for CD11b, F4/80, CD68, and Iba1, but also by
their activated and amoeboid morphology (42)] (Fig. 5 C, Right).
In stark contrast, there was virtually no microgliosis appreciated
following injection of SDV1a despite its extensive contempora-
neous chemoattractive pull on the hNSCs (Fig. 5 C, Left). As in
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Fig. 5. SDV1a’s chemoattraction for hNSCs is CXCR4-
specific, stable, persistent, widespread, and benign,
provoking no inflammatory reactive microgliosis. (A)
SDV1a persists in vivo in a widespread distribution
for 3 wk postinjection. SDV1a was tagged with either
FITC (green fluorescence) (Left) or biotin (revealed by
reaction with Avidin-HRP to produce a brown pre-
cipitate) (Right; magnified in the respective Insets).
SDV1a was injected into the regions shown in the
schematics. Three weeks later, the brains were an-
alyzed for persistence of the widely distributed
SDV1a, as visualized by the tags. Representative
photomicrographs are shown from the corre-
sponding regions indicated in the schematic. SDV1a
was detectable in all injected regions up to 3 wk
postadministration as indicated by either green
fluorescence (all cells in the field shown by a blue
DAPI nuclear stain) (Left) or by a brown precipitate
(all cells in the field seen as purple on this H&E stain)
(Right). The distribution of the engrafted hNSCs in
Fig. 4, Left, was congruent with the distribution of
SDV1a as detected here. The hNSCs persisted for the
lifetime of the animal although the peptide disap-
pears after 3 wk. (Scale bars, 25 μm.) (B) Blockade
of CXCR4 (Left), but not of CXCR7 (Right), on
transplanted hNSCs inhibits their migration toward
SDV1a. Arrows in the schematic indicate sites of
hNSC and SDV1a injections. Prior to transplantation,
the hNSCs were preincubated ex vivo with either the CXCR4 inhibitor AMD3100 (Left) or the CXCR7 inhibitor CCX771 (Right), exposure to which continued
for 24 to 72 h postgrafting in vivo via an osmotic pump implanted at the site of transplantation. As early as 3 d posttransplant, hNSCs treated with the
CXCR7 inhibitor had nevertheless migrated entirely to the contralateral side (hippocampus in this case), as indicated by the presence of hMito+ cells (red)
(Right) (similar to Fig. 4, Left); arrow indicates one such cell. In contrast, no hNSCs treated with the CXCR4 blocker were detectable there (Left), indicating
that CXCR4 inhibition blocked the migration of engrafted hNSCs toward the SDV1a sites in mouse brain. As expected, no hNSCs were seen when PBS was
injected instead of SDV1a as a sham control. All cells in the field are visualized by a DAPI (blue) nuclear stain. (Scale bars, 10 μm.) These data suggested that
SDV1a was acting highly specifically through CXCR4 directly on the hNSCs and not through other chemokine receptors or through intermediaries (e.g.,
receptors on macroglia, microglia, extracellular matrix, vascular endothelia, and so forth). (C ) Brains treated with CXCL12/SDF1α (Right) but not those
treated with SDV1a (Left) engendered widespread abundant activated microgliosis. Activated M1 microglia are shown here as immunopositive for CD11b
(red), but were similarly detected by antibodies to F4/80, CD68, and Iba1. Such microgliosis persisted as long as 2 wk postinjection. The Inset shows a high-
power view from the field (white arrow) of a typical activated M1 microglial cell. The region shown (i in the schematics) in both conditions is representative
of all areas exposed to SDV1a vs. CXCL12. An average of 11.7 ± 2.8 per 0.4 mm2 CD11b+ cells were present following an injection of native CXCL12
compared to only 1.1 ± 1.0 CD11b+ cells per 0.4 mm2 following an injection of SDV1a (a number comparable to the healthy adult murine brain). All cells in
the field are visible by the DAPI (blue) nuclear stain. (Scale bars, 10 μm; 5 μm in the Inset). (n = 3 mice in each condition) (See also Fig. 7B for a similar
demonstration of a lack of activated microgliosis in response to SDV1a.).
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previous studies (1–5, 43), transplanted NSCs themselves do not
provoke an inflammatory reaction, even without immunosup-
pression, likely because—at the differentiation state at which the
cells are implanted—they do not express MHC class II (43).
Mice were entirely normal histologically, physiologically, and
behaviorally. (Note that, in these experiments in healthy adult
mice, the blood–brain barrier was intact; the needle itself was so
fine and applied so noninvasively that not even local trauma was
induced by the injection. Therefore, infiltration of inflammatory
cells from the peripheral circulation, such as lymphocytes and
macrophages, would not be expected.)
Despite its wide distribution and long-term stability in recipi-
ent brains, SDV1a did not disrupt the blood–brain barrier; cause
host cell death, abnormal host cell proliferation, distortion of
host cytoarchitecture, or tumor formation; draw cells into the
brain that do not belong there (including peripheral blood
macrophages); or traffic to other organs, such as kidney, liver,
lung, or spleen. Mice showed no evidence of systemic or CNS
toxicity or altered behavior. As explored in greater detail below
(and in Fig. 8 and SI Appendix, Fig. S9) the differentiation fate of
hNSCs was unaltered, including, where appropriate, into elec-
trophysiologically active neurons. Importantly, as noted above on
a cellular level for hNSCs (SI Appendix, Figs. S6 and S7), SDV1a
did not induce a proinflammatory gene-expression profile within
the adult mouse brain as a whole, in contrast to injected
recombinant CXCL12, which did promote such a profile. In
other words, injection of SDV1a, whether in conjunction with
hNSC transplantation or alone, produced no inflammation. In-
terestingly, in the uninjured adult murine brain, SDV1a alone
did not appear to draw endogenous host murine CXCR4-
expressing cells to its location (the number of such cells in the
SDV1a-injected cortex or hippocampus did not differ from that
in the corresponding uninjected contralateral structure of the
same mice or in homotopic regions of age-matched uninjected
mice). The explanation for an absence of any redistribution of
endogenous neural cells seemed simply to be that, in the intact
adult mouse brain parenchyma, the cells expressing CXCR4 are
not migratory NSCs, but rather well-integrated mature neural
cells, largely neurons (SI Appendix, Fig. S8); in fact, the endog-
enous Nestin+ NSCs in the adult brain parenchyma did not ex-
press CXCR4 (SI Appendix, Fig. S8). A rigorous study of this
phenomenon of differential CXCR4 expression by cells of dif-
ferent phenotypes and different developmental ages in different
brain regions under different conditions is beyond the scope of
this paper; suffice it to say, this relatively selective effect of
SDV1a in hNSC transplantation paradigms may further support
its safety profile. In the disease model we describe below (Figs.
6–8 and SI Appendix, Fig. S9), SDV1a’s use (including any
changes on endogenous cells below our level of detection)
enhanced—and in no way hindered—the efficacy of a cell based-
therapy.
Persistence of SDV1a in the CNS parenchyma, taken together
with slow hNSC CXCR4 receptor turnover, strong affinity for
the CXCR4 binding pocket, and a benign noninflammatory
surrounding milieu, likely accounted for the stable presence of
donor hNSCs in response to SDV1a, even in a typically non-
neurogenic, nonmigration-supporting region. The instability of
recombinant CXCL12 in a physiological environment (8, 41, 42),
either because of its enzymatic degradation or the toxic inflam-
mation it engenders, likely explains why it did not promote
similar long-distance donor hNSC migration and integration
within the host cortex.
Coadministration of SDV1a with hiPSC-Derived hNSCs Renders Them
more Therapeutic. We next determined whether such properties
would enable SDV1a to circumvent a therapeutic obstacle. A
long-standing challenge to regenerative medicine has been en-
hancing and directing the migration of therapeutic cells to re-
gions in need (11, 12). (This obstacle has recently become
particularly salient with the recognition that, for unknown rea-
sons, hiPSC derivatives, although gaining in popularity for
therapeutic transplants, migrate poorly compared to their pri-
mary or human embryonic stem cell [hESC] counterparts.) To
assess whether a “chemo-mimetic” strategy could address this
challenge, we elected to approach a disease model in which
unambiguous measures of therapeutic success: 1) Pivot on ade-
quate migration of hNSCs from their site of implantation to
distant regions mediating key functions (e.g., the cortex); 2)
demand wide-spread dissemination and integration of donor
cells in those regions to affect improvement, and where the de-
gree of benefit correlates with the extent of migration and in-
tegration of donor cells; 3) require that inflammation not be
exacerbated, given that a prominent inflammatory signature al-
ready contributes to the pathophysiology; and 4) constitutive,
spontaneous migration of grafted cells is limited. LSD mouse
models nicely fit these criteria (1, 38). Indeed, lack of efficacy in
some stem cell-based clinical trials for neuropathic LSDs have
been attributed, in part, to inadequate coverage of diseased
terrain by transplanted corrective cells (32). Furthermore, given
the recently reported toxicity of viral vectors, such as AAV9, at
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Fig. 6. Transplantation of hiPSC-derived hNSCs into the brains of Sandhoff
(Hexβ−/−) mice prolonged life, delayed onset of symptoms, and preserved
motor function most significantly when grafting was accompanied by co-
administration of SDV1a to insure distribution of Hex-producing cells
throughout the mutant cortex. (A) Motor function deteriorated (as mea-
sured by rotarod) in 3-mo-old untreated Sandhoff disease mice (green
squares, n = 14). While the intraventricular transplantation (Tx) of hiPSC-
hNSC forestalled symptomatic collapse by ∼2 wk (black circles, n = 22; P <
0.001 by t test compared to untreated Sandhoff diesease mice), this period
was significantly less than the 4-mo symptom-free period we previously
reported using primary CNS- and hESC-derived hNSCs (1). (Data represent
mean ± SEM). hiPSC-derived hNSCs are known to have more limited mi-
gratory ability. However, coadministration of the hiPSC-hNSCs and the
SDV1a peptide (B) forestalled loss of motor function until at least 4 mo with
no significant decline until 18 wk in transplanted Sandhoff disease mice
(blue circles, n = 14) [P < 0.001, t test compared to hiPSC-hNSC Tx Hexβ−/−
mice without SDV1a (black circles) and compared to control untreated
Hexβ−/− mice (green squares); mean ± SEM]. Performance of WT mice is
shown as pink triangles (n = 12). (C) Survival (shown as Kaplan–Meier curves)
of hiPSC-hNSC–transplanted Sandhoff disease mice without (black triangles,
n = 22) and with (purple squares, n = 14) coadministration of SDV1a com-
pared with untreated Hexβ−/− mice (orange circles, n = 14). While hiPSC-
hNSC transplanted Sandhoff disease mice without SDV1a did survive ∼3
wk longer (to 150 d) (P < 0.0001, log rank test), those coadministered with
SDV1a at the time of the hiPSC-hNSC transplant had a much longer life span,
by ∼1.5 mo to 5.5 mo (P < 0.0001, log rank test), a survival similar to that
reported for CNS- and hESC-derived hNSCs (1). All hiPSC-hNSC transplanted
Sandhoff disease mice were alive when all untreated Sandhoff disease mice
had already died (131 d). Fibroblast transplantation yields survival and
function curves indistinguishable from untreated Sandhoff disease mice, as
we previously reported (1).
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the high doses required for widespread CNS gene replacement
(33), cell-based gene therapy will likely play an even more
prominent role in these conditions.
Of the neuropathic LSDs, we elected to approach Sandhoff
disease (1) not only because this lethal neurodegenerative dis-
order provides a stringent, rapid, and unambiguous test for a tool
to enhance stem cell migration and chimerism, but also because
we have a rich database on this model, having studied it exten-
sively (1). In addition, the largely invariant natural history of
patients with this condition (for which the mouse model is ex-
cellently representative) is well-established. Sandhoff disease is a
rapidly progressive lethal neurodegenerative condition charac-
terized by a deletion mutation of the gene encoding the β-chain
of the secreted diffusible lysosomal enzyme β-hexosaminidase
(Hex), leading to absence of both its dimeric isoforms, Hex A
and Hex B. This complete absence of Hex results in intra-
neuronal ganglioside storage and inflammation, leading to in-
exorable neuronal death and neurological demise.
We previously reported (1) that exogenous normal hNSCs—
whether derived from hESCs or isolated directly from the
CNS—when transplanted into the cerebral ventricles of newborn
Sandhoff disease (Hexβ−/−) mice, integrated into the sub-
ventricular zone and, from there, migrated extensively through-
out the brain, forestalling disease onset, preserving function, and
substantially extending life. We profiled the multiple mecha-
nisms by which hNSCs imparted this benefit (4): 1) They con-
stitutively produced Hex A and B, which was endocytosed by
mutant cells via their mannose-6-phosphate (M6P) receptor,
restoring normal metabolism; 2) they reduced ganglioside stor-
age within host neurons by virtue of this cross-correction; 3) they
replaced a small number of degenerating neurons as well as glia;
and 4) they diminished inflammation. The success of these ac-
tions was dependent on widespread dissemination and integra-
tion of the exogenous NSCs, particularly in the cortex where a
threshold density of donor-to-host cells was required: A 1:10
ratio conferred whole-brain Hex activity that was >3 to 5% of
WT, a threshold level sufficient to restore normal metabolism
(1), even achieving levels as high as 28% of WT Hex activity in
areas of densest hNSC chimerism (4). hNSCs derived from
hiPSCs (44) have not yet been tested in this model, although our
expectations were modest given the growing concern regarding
hiPSC migration. Normally, for a monogenic disease, one would
not want to use autologous cells for a cell-based treatment given
that those cells also bear the enzyme deficiency. However, the
potential appeal of patient-specific hiPSCs in this situation,
particularly in view of the latter-day ease of correcting monogenic
defects by either genome editing or virus-mediated transgene
transfer, was that immunocompatible hiPSCs could be reinjected
periodically throughout a patient’s life as the brain grows or donor-
derived cells die without the risk of immunorejection. A first
E
*
** **
hiPSC-
hNSC Tx
(Hexß -/-)
Control
(Hexß -/-)
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hNSC Tx
(Hexß -/-)
+ SDV1a
Iba1 / DAPI
C
GM2 / DAPI
hMito / Iba1 / DAPINon-Tx Tx
Non-Tx TxGM2 / DAPI
D
Fig. 7. hiPSC-hNSC-mediated mechanisms of improvement (enhanced
by SDV1a) remain like those of other hNSCs (1): Enzyme replacement,
GM2 ganglioside storage reduction, and suppression of inflammation. (A)
Sandhoff disease is characterized by an intense activated microgliosis, as
demonstrated by the density of cells expressing the M1 microglial marker
Iba1 (green, arrows) in the cortex of this representative untransplanted
(non-Tx) 4-mo-old Sandhoff disease mouse. (Iba1+ cells indicated by the ar-
rows are magnified in the Inset to better visualize their microglial mor-
phology). (B) In contrast, in age-matched Sandhoff disease mice that
received hiPSC-hNSCs transplanted (Tx) into the cerebral ventricles and
SDV1a coadministered into the cortex, wherever engrafted donor-derived
cells were present (as confirmed here by their immunoreactivity to an anti-
body against hMito; red, white arrows), such microgliosis was scant. (The
distribution of the donor hNSC-derived hMito+ cells was like that shown in
Fig. 4). (Scale bars in A and B, 20 μm; in Inset, 5 μm.) (C) Representative
confocal photomicrograph showing significant amounts of immunoreactive
GM2 ganglioside storage (green, arrows) in the same cortical region shown
in A from the same representative 4-mo-old untransplanted Sandhoff dis-
ease mouse. (D) In contrast, little GM2 accumulation occurred in the same
region of an age-matched Sandhoff disease mouse transplanted (Tx) with
hiPSC-hNSCs coadministered with SDV1a (same mouse and region as in B).
DAPI nuclear stain (blue) marked all cells shown. (Scale bar, 20 μm.) The
images in A–D are orthogonal projections composed of 9 to 16 optical
z-planes of thickness 0.5 to 1 μm. n = 6 animals per experiment group. (E)
To provide a mechanistic basis for the observations in A–D, we demonstrated
that Hex enzyme levels in the CNS parenchyma of Sandhoff disease mice
were raised beyond the critical 3 to 5% therapeutic threshold in regions
where donor cells were attracted by SDV1a to integrate as opposed to re-
gions where they were not (i.e., transplanted but without SDV1a coadmin-
istration). The Hex levels in the hiPSC-hNSC+SDV1a Sandhoff disease mice
were significantly higher than those in SD mice transplanted but without
SDV1a or in untransplanted Sandhoff disease mice (*P < 0.05, **P < 0.01 by
two-tailed t test). The donor-to-host cell ratio in engrafted regions was 1:10,
as previously reported (1).
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transplant, even with allogeneic NSCs (as we reported in newborns
and adults) does not require immunosuppression (1, 3, 43); however,
subsequent reimplantation of the same NSCs does run the risk of
rejection based on prior sensitization. Hence determining the efficacy
and safety of hiPSCs for this condition seemed justified.
The consensus view is that, when using NSCs to address a
global encephalopathy requiring extensive chimerism, instillation
into the cerebral ventricles (particularly of newborn or juvenile
brains), is superior to multiple intraparenchymal injections for
minimizing invasiveness while maximizing efficacy (1, 38). (In-
travascular routes have not been successful for enzyme or cell
replacement in this neuropathic LSD.) It initially seemed trivial
to replicate our previously reported intraventricular approach (1,
38), now simply using hNSCs derived from normal hiPSCs,
neuralized according to well-accepted published protocols (34,
45). However, such hiPSC-derived hNSCs (hiPSC-hNSCs), as
feared, were more limited in their migratory capacity compared
to primary CNS- and hESC-derived hNSCs (1), an observation
suggested by others (46, 47). In our case, the hiPSC-derived
hNSCs did not migrate to the cortex from their implantation
site in the ventricles, severely limiting their efficacy for Sandhoff
disease. In other words, although engrafted Hex-expressing
hiPSC-derived hNSCs did increase life span and improve mo-
tor function of the Sandhoff disease mice somewhat (Fig. 6),
their impact was inferior to that from primary CNS- and
hESC-derived hNSCs (4) due to their limited migration from
periventricular regions to the cortex. This limitation was
replicated using different hiPSC lines from different suppliers
neuralized using different accepted protocols (SI Appendix,
Detailed Experimental Procedures). We viewed it as beyond the
scope of this work to determine the reason for this more
limited migration. It may represent a component of residual
epigenetic memory or the consequences of the genetic manipu-
lation inherent in reprogramming; suffice it to say that, in using
accepted and oft-used published generation and differentiation
protocols, we eliminated “technique” as a confounder. Rather,
we accepted this consistent observation by us and others (46, 47)
of restricted migration as a potential limitation to hiPSC-based
therapies for these types of neural transplantation challenges,
and rather viewed this obstacle as an opportunity to demonstrate
that a synthetic chemokine agonist could effectively optimize
the impact of cell-based therapies by enhancing migration (a
demanding proof-of-concept).
Indeed, when hiPSC-derived hNSCs were implanted into the
cerebral ventricles of neonatal Hexβ−/− mouse brains contem-
poraneously with the minimally invasive administration of 1 μL
of 3.2 μM SDV1a into each hemisphere’s superficial dorsal
cortex via a finely drawn glass micropipette (by barely puncturing
the meninges, as we had done with normal adult mice in Fig. 4),
we now observed wide dissemination of corrective donor-derived
neural cells (which constitutively expressed fully assembled and
active Hex A and B) throughout the diseased brain (1) (Fig. 7;
and as per Fig. 4) with a significant therapeutic impact, now
comparable to what we previously reported for other sources of
hNSCs (1). This impact included delayed disease onset, pre-
served motor-function [as assessed by rotarod (1, 2)], prolonged
symptom-free survival, and extended lifespan (Fig. 6). Hex activity
was now measurable throughout the cortex (Fig. 7, histograms)
with the donor-to-host cell ratio cited above, as we previously
reported (4); host intraneuronal glycosphingolipid (GSL) mono-
sialoganglioside (GM2) storage was reduced at 2-mo of age (as mea-
sured using the standard biochemical reaction, immunohistochemistry,
A B
C
D
E
Fig. 8. Fate of the donor-derived hiPSC-hNSCs in vivo not compromised
when coadministered with SDV1a. Although the most dominant mecha-
nisms for improving survival and function (as in Fig. 6) are cell-mediated
provision of Hex (Fig. 7E), reduction in host intracellular GM2 accumula-
tion (Fig. 7 C and D), and blunting microgliosis (Fig. 7 A and B), we also
confirmed the integration of hiPSC-hNSC derivatives into the host
cytoarchitecture in a functionally and cell-type appropriate manner in con-
junction with the administration of SDV1a. A more complete survey is pro-
vided in SI Appendix, Fig. S9. Shown here is the demonstration that neurons
derived from hiPSC-hNSCs are electrophysiologically active and receive both
excitatory and inhibitory synaptic inputs. (A) Low-power image of hippo-
campus showing the location of a representative recorded cell. Hippocampal
subfields are labeled: dentate gyrus (DG), CA3, and CA1. (B) Fluorescence
images of a recorded eGFP+ donor-derived cell (green) in a cortical slice from
a representative 2-mo-old Hexβ−/− mouse engrafted with eGFP-expressing
hiPSC-hNSCs at birth with coadministered SDV1a. The cell has been filled by
Alexa 555 (red) in the recording pipette. Note the filled neurites extending
from the cell body. Recordings from this cell are shown in C–E. (Scale
bars,100 μm for A, 40 μm B.) (C, Left) Current-clamp recording of an eGFP+
cell showing spontaneous action potentials (APs). (C, Right) Recording from
the same cell with APs produced by injecting depolarizing current. (D, Left)
Voltage clamp recording in tetrodotoxin (TTX), a Na+ channel blocker, to
suppress APs and hold the cell at 0 mV to eliminate excitatory synaptic
currents and allow visualization of spontaneous inhibitory postsynaptic
currents (IPSCs). Upper traces are shown at a compressed timescale. The trace
framed by the gray boxes are expanded in the Lower trace. (Right) A
demonstration that IPSCs can be eliminated by washing in SR95531, a
GABAA receptor antagonist. (E, Left) Same cell as in D, held at −80 mV to
reveal excitatory postsynaptic currents (EPSCs). (Right) A demonstration that
EPSCs can be eliminated by DNQX and APV, AMPA and NMDA receptor
blockers, respectively.
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and HP-TLC) compared to untransplanted age-matched Hexβ−/−
littermates, as well as Hexβ−/− littermates transplanted without
coadministration of SDV1a (Fig. 7). No GM2 was detected in
normal mouse brains (Fig. 7 C and D). In addition, inflammation
within theHexβ−/− cortex was actually diminished [attributable to
the previously documented (1, 2, 38) and now well-accepted
immunomodulatory actions of hNSCs (5)] with no additional
inflammation or microgliosis having been induced by the SDV1a
(Fig. 7 A and B). Furthermore, SDV1a did not antagonize the
antiinflammatory actions of the hNSCs.
Five percent (±1%) of donor-derived hNSCs differentiated
into neurons in the cortex with appropriate electrophysiological
properties (Fig. 8), a proportion we had similarly observed for
primary CNS-derived and hESC-derived hNSCs (1). Although
such neurons were not central to the therapeutic impact of the
hiPSC-hNSCs in this disease model, their presence reaffirmed
that SDV1a did not alter the differentiation profile of hNSCs, or
the ability of their derivatives to integrate into host cytoarchi-
tecture in a functionally and cell type-appropriate manner, or their
mechanisms-of-therapeutic-action in the Sandhoff disease mouse
model. All SDV1a appeared to change was the distribution of the
implanted hiPSC-derived hNSCs, allowing them to cover, and hence
rescue, a broader critical terrain of mutant brain, thus enhancing the
hiPSC-derived hNSC’s therapeutic impact on this disease.
For completeness, we found that the remainder of the hiPSC-
hNSC differentiation pattern in the engrafted SDV1a exposed
brains (n = 35) was also similar to what we previously reported
for primary CNS- and hESC-derived hNSCs (4) (39% expressing
astroglial markers, 2% oligodendroglial markers, 54% markers
of undifferentiated neural progenitors) (SI Appendix, Fig. S9).
No other cell types (including nonneural lineages) were repre-
sented. All cells expressed Hex. No tumors, cell overgrowth,
distortion of host cytoarchitecture, or hemorrhages were ob-
served. (Although beyond the scope of this study, an effective
long-term cell-based treatment of this condition may entail pe-
riodic readministration of hiPSC-derived neural cells at cardinal
time points throughout a patient’s life when Hex levels dip below
a certain threshold or symptoms recur as the brain grows and
WT cells senesce and die.)
Discussion
In summary, we have explored a strategy for directing the mi-
gration of transplanted stem cells, particularly hiPSC-derived
hNSCs, by harnessing one of stem cell biology’s fundamental ac-
tions, pathotropism, as mediated by inflammatory chemokine–
receptor interaction. As proof-of-concept that one can develop a
bifunctional ligand that divorces inflammatory signaling from
migratory signaling as well as from binding, we developed, through
chemical mutagenesis of the prototypical cytokine CXCL12, a
“dual-moiety” prototypic synthetic CXCR4 agonist peptide that
contains a maximal selective receptor binding motif linked to a
modified and shortened CXCR4-activating motif of higher sig-
naling specificity. We documented significant advantages of the
synthetic agonist over recombinant versions of the natural CXCR4
agonist CXCL12 in the mouse brain in terms of distribution,
stability, inflammogenesis, duration of chemoattraction and, most
importantly, extent and success of migratory guidance of engrafted
CXCR4-expressing stem cells, such as hNSCs. As evidence of
its translational value, we used the peptide to guide engrafted
hiPSC-derived hNSCs, whose own migratory repertoire ap-
pears limited, toward sites of CNS pathology, alleviating
symptoms, preserving function, and prolonging life in a mouse
model of a prototypical neurodegenerative disorder. Impor-
tantly, microgliosis and inflammation were actually sup-
pressed, not provoked; that is, the antiinflammatory action of
the hNSCs was not contravened by the CXCL12-mimetic as
might have been feared. (In many neurodegenerative diseases
there is strong evidence for an inflammatory response initiated
by microglial activation leading to neuronal apoptosis.) To our
knowledge, this synthetic chemokine agonist designed, char-
acterized, and validated in a translationally relevant system is
unique. [Of note, one would actually not want to test this
phenomenon in an acute focal traumatic injury model be-
cause, as we’ve previously shown (2–5, 48), migratory signals
from a reservoir of concentrated inflammatory cues, as in the
epicenter of a circumscribed lesion, already abets likely ade-
quate migration, although one could certainly optimize it with
this peptide. One wants to test proof-of-concept in a dra-
matically deficient model, as we’ve done here.]
Since CXCR4 is present on most stem cells in most organs,
SDV1a could be useful outside the nervous system as well for
directing stem cells from a range of derivations for many pathological
conditions (5–12, 49–54). Furthermore, because signaling between
CXCL12 and CXCR4 is an oft-explored axis, having been implicated
in a number of degenerative CNS diseases and other disorders (5–12,
49–54), the agonist may be useful as a molecular probe for further
understanding ligand-GPCR signaling in studying pathogenic
mechanisms (21). Additionally, this approach of subjecting
inflammatory chemokines to chemical mutagenesis to maxi-
mize desirable properties (e.g., homing) and minimize undesirable
characteristics (e.g., inimical inflammatory reactions) could be
applicable to other chemokines. Other chemokine receptors are
thought to have a two-site interaction with their ligand similar to
that we exploited for CXCR4 (18–20). Moreover, many of these
sites are druggable.
In short, off-the-shelf, reasonably priced, broadly applicable
chemokine analogs and chemokine–receptor agonists with
in vivo stability, potent chemoattraction without inflammogenesis
or adverse off-target actions, and with established efficacy, effi-
ciency, tolerability, and safety in pathologic conditions requiring a
specific distribution and location of therapeutic cells should pro-
vide regenerative medicine with another tool. In the CNS, one
might envision using such a novel GPCR-targeted medication
when reparative stem cells (producing therapeutic molecules,
scavenging or neutralizing toxins, enhancing remodeling, provid-
ing therapeutic structures like myelin, or replacing cells) must: 1)
Be directed to needed regions (e.g., the cortex in dementing
disorder); 2) be more widely distributed to broaden their chimerism
(e.g., throughout the spinal cord in neuromuscular diseases, such as
amyotrophic lateral sclerosis); 3) be more homogeneously distrib-
uted within a given organ to avoid overly concentrated niduses of
cells (e.g., dopamine-expressing cells in the striatum of Parkinsonian
patients); 4) have a permissive milieu recreated for them within
chronically injured microenvironments where proreparative cues
have abated. In addition, blunting undesirable signaling as we did
here may be useful in other systems: For example, chimeric antigen
receptor T-cell antineoplastic immunotherapy in order to minimize
the adverse effects of cytokine (“storm”) release syndrome (55, 56).
Methods
To synthesize SDV1a, the first 21 amino acids (all in a D-chirality) from the
N-terminal of the CXCR4 antagonist vMIP-II were inserted in place of
CXCL12’s proximal N terminus to provide a ligand with the highest affinity
for the binding pocket. The distal N-terminal signaling motif of CXCL12,
which engages the signaling pocket, was truncated to the first 8 amino acids,
narrowing the spectrum of G protein-mediated pathways activated. After
affirming SDV1a’s specificity and efficacy in CXCR4 competition assays, it was
injected into regions of normal adult mouse brain and of the brains of Sandhoff
disease mice into which we cotransplanted hNSCs to home and engraft.
Data Availability. All study data are included in the article and supporting
information. All materials and protocols are available from E.Y.S., Z.H., or J.-P.L.
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